AQR Capital Management LLC grew its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 567.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,080 shares of the biopharmaceutical company’s stock after purchasing an additional 170,960 shares during the quarter. AQR Capital Management LLC owned about 0.19% of Revance Therapeutics worth $517,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of RVNC. Certuity LLC purchased a new position in Revance Therapeutics in the 2nd quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC purchased a new position in Revance Therapeutics in the 2nd quarter worth approximately $33,000. Hsbc Holdings PLC purchased a new position in Revance Therapeutics in the 2nd quarter worth approximately $38,000. Nisa Investment Advisors LLC lifted its stake in Revance Therapeutics by 2,167.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 18,077 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in Revance Therapeutics by 52.5% in the 2nd quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 7,628 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.
Revance Therapeutics Stock Performance
Revance Therapeutics stock opened at $5.14 on Tuesday. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $9.90. The firm has a 50 day moving average price of $5.82 and a 200 day moving average price of $4.26. The company has a market capitalization of $538.77 million, a PE ratio of -1.61 and a beta of 0.98.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the stock. Needham & Company LLC downgraded shares of Revance Therapeutics from a “moderate buy” rating to a “hold” rating in a report on Tuesday, August 13th. HC Wainwright downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 13th. StockNews.com assumed coverage on shares of Revance Therapeutics in a report on Wednesday, October 9th. They set a “hold” rating for the company. Barclays restated an “equal weight” rating and set a $7.00 price target (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Finally, Piper Sandler downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $10.29.
Read Our Latest Stock Report on Revance Therapeutics
Revance Therapeutics Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
See Also
- Five stocks we like better than Revance Therapeutics
- ESG Stocks, What Investors Should Know
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Comparing and Trading High PE Ratio Stocks
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- What Is WallStreetBets and What Stocks Are They Targeting?
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report).
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.